BioArctic Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	4.1yrs
Board average tenure	10.4yrs

Recent management updates

Recent updates

CEO

BioArctic has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pär Gellerfors	Co-Founder	21.3yrs	kr390.00k	0% SEK 0
Lars Lannfelt	Co-Founder	21.3yrs	kr2.54m	33.43% SEK 5.8b
Anders Martin-Lof	Chief Financial Officer	less than a year	no data	no data
Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	18.3yrs	no data	0.063% SEK 11.0m
Oskar Bosson	VP and Head of IR & Communication	3.9yrs	no data	0.012% SEK 2.0m
Leif Gallo	General Counsel	no data	no data	no data
Harald Borgeke	Head of Public Affairs	2yrs	no data	no data
Frida Lekander	Head of Marketing	2.2yrs	no data	no data
Gunilla Andersson	Vice President of Human Resources	5.3yrs	no data	no data
Johanna Fälting	VP & Head of Research	no data	no data	0.054% SEK 9.5m
Tomas Odergren	Chief Medical Officer	4.3yrs	no data	0.0065% SEK 1.1m
Anna-Kaija Gronblad	Chief Commercial Officer	3.3yrs	no data	0.011% SEK 1.8m

4.1yrs

Average Tenure

63yo

Average Age

Experienced Management: 0RV2's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pär Gellerfors	Co-Founder	21.3yrs	kr390.00k	0% SEK 0
Lars Lannfelt	Co-Founder	21.3yrs	kr2.54m	33.43% SEK 5.8b
Eugen Steiner	Independent Chairman	6.6yrs	kr621.00k	0.091% SEK 15.8m
Hans Wigzell	Member of Scientific Advisory Board	no data	no data	no data
Konrad Beyreuther	Member of the Scientific Board	no data	no data	no data
Mikael Smedeby	Independent Director	5.9yrs	kr316.00k	0.031% SEK 5.4m
Ivar Verner	Independent Vice Chairman	14.3yrs	kr406.00k	0.14% SEK 24.2m
Charlotta Ljungqvist	Independent Director	2.9yrs	kr318.00k	0.0036% SEK 624.5k
Martin Ingelsson	Member of Scientific Board	no data	no data	no data
Staffan Pauli	Member of Scientific Advisory Board	no data	no data	no data
Ken Marek	Member of Scientific Advisory Board	no data	no data	no data
Kaj Blennow	Member of Scientific Advisory Board	no data	no data	no data

10.4yrs

Average Tenure

74yo

Average Age

Experienced Board: 0RV2's board of directors are seasoned and experienced ( 10.4 years average tenure).

BioArctic Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Chairman recently bought kr1.1m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

VP & Head of Research recently sold kr6.5m worth of stock

Recent updates

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

New minor risk - Share price stability

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Independent Director recently sold kr3.3m worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released: EPS: kr1.55 (vs kr0.43 loss in 3Q 2021)

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Insider recently bought kr100k worth of stock

First quarter 2022 earnings released

Insufficient new directors

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Independent Deputy Chairman recently bought kr824k worth of stock

Bioarctic AB Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Third quarter 2021 earnings released

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Chief Medical Officer recently bought kr103k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

First quarter 2021 earnings released: kr0.33 loss per share (vs kr0.04 profit in 1Q 2020)

Bioarctic and Eisai Present Latest Data Regarding Lecanemab at AD/PD 2021

Bioarctic AB (Publ) and Eisai to Present Data Relating to Its Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody Lecanemab (BAN2401)

BioArctic AB (publ) Announces Board Changes

Full year 2020 earnings released: kr0.78 loss per share (vs kr1.01 profit in FY 2019)

Revenue beats expectations

BioArctic AB (publ) to Report Fiscal Year 2020 Final Results on Mar 31, 2021

BioArctic AB Increases the Number of Participants in Clarity AD Study

New 90-day high: kr122

BioArctic AB (publ) to Report Nine Months, 2021 Results on Oct 21, 2021

Third quarter earnings released

New 90-day high - kr94.00

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure